AI Terminal
ARECOR THERAPEUTICS PLC
Regulatory Filings • Nov 10, 2022
7494_rns_2022-11-10_4c0bcdcc-6a92-43d6-b65f-879f1a2902c3.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 9078F
Arecor Therapeutics PLC
10 November 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR ANNOUNCES EXCLUSIVE SPECIALTY HOSPITAL FORMULATION COLLABORATION
Cambridge, UK, 10 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with the pharmaceutical division of one of the world's largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.
Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a differentiated, stable, liquid drug product, for intravenous administration, that is Ready-to-Use ("RTU"). The new liquid formulation of the product supports safe medication practices and operational efficiency by eliminating the need for reconstitution. The partner will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model to further develop and commercialise the product.
This collaboration adds to Arecor's growing portfolio of pre-license technology partnerships which, subject to licensing, typically include both potential milestone and royalty payments and could offer significant future recurring revenue upside potential for the Group.
Sarah Howell, Chief Executive Officer of Arecor, said: "This collaboration further demonstrates the strength of our proprietary technology platform, Arestat™, and its potential in the development of Ready-to-Use medicines. This is a field in which Arecor is building a considerable portfolio of potential specialty hospital products, as well as bringing our technology and experience to further our partners' products. Our expertise in formulating complex medicines, when combined with our partner's global network and specific local knowledge of providing access to the major markets worldwide, will be key to advancing these fast, safe and effective treatments for patients."
-ENDS-
For more information, please contact:
| Arecor Therapeutics plc | www.arecor.com |
| Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Susan Lowther, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Mo Noonan, Communications | Tel: +44 (0) 7876 444977 Email: [email protected] |
| Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500 |
| Consilium Strategic Communications | |
| Chris Gardner, David Daley, Angela Gray | Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCFFFLILFLAIIF